Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.72 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14709881 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1HCAR2KDM4EPOLB | |
| SCHEMBL28350442 | 0.96 | CHRM2 (0.75) | CHRM2CHRM1HCAR2KDM4EPOLB | |
| Fumaric Acid SCHEMBL16341383 | 0.94 | CHRM2 (0.75) | CHRM2CHRM1HCAR2KDM4EPOLB | |
| SCHEMBL17486755 | 0.91 | CHRM2 (0.68) | CHRM2CHRM1HCAR2KDM4EPOLB | |
| Fesoterodine SCHEMBL814971 | 0.90 | CHRM2 (0.90) | CHRM2CHRM1HCAR2KDM4EPOLB | |
| Fesoterodine SCHEMBL31043343 | 0.90 | CHRM2 (0.90) | CHRM2CHRM1HCAR2KDM4EPOLB | |
| Fesoterodine SCHEMBL1993629 | 0.90 | CHRM2 (0.90) | CHRM2CHRM1HCAR2KDM4EPOLB | |
| Fesoterodine SCHEMBL1993632 | 0.90 | CHRM2 (0.90) | CHRM2CHRM1HCAR2KDM4EPOLB | |
| SCHEMBL723472 | 0.89 | CHRM2 (0.82) | CHRM2CHRM1KDM4EPOLBCHRM3 | |
| SCHEMBL723471 | 0.89 | CHRM2 (0.82) | CHRM2CHRM1KDM4EPOLBCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751828-B2 | Antimuscarinic compound having a low content of impurities | DIPHARMA FRANCIS S.R.L. (IT) | 2017-09-05 | — | — | US | disclosed |
| US-9751828-B2 | Antimuscarinic compound having a low content of impurities | DIPHARMA FRANCIS S.R.L. (IT) | 2017-09-05 | — | — | US | disclosed |
| EP-2251318-B1 | Method for preparing fesoterodine fumarate | CHEMI SPA (IT) | 2016-06-08 | — | — | EP | disclosed |
| US-9272982-B2 | Method for preparing high-purity fesoterodine fumarate | CHEMI S.P.A. (IT) | 2016-03-01 | — | — | US | disclosed |
| US-9272982-B2 | Method for preparing high-purity fesoterodine fumarate | CHEMI S.P.A. (IT) | 2016-03-01 | — | — | US | disclosed |
| US-20160031796-A1 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES | DIPHARMA FRANCIS S.R.L. (IT) | 2016-02-04 | — | — | US | disclosed |
| US-20160031796-A1 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES | DIPHARMA FRANCIS S.R.L. (IT) | 2016-02-04 | — | — | US | disclosed |
| US-20140303396-A1 | Method for Preparing High-Purity Fesoterodine Fumarate | CHEMI S.P.A. (IT) | 2014-10-09 | — | — | US | disclosed |
| US-20140303396-A1 | Method for Preparing High-Purity Fesoterodine Fumarate | CHEMI S.P.A. (IT) | 2014-10-09 | — | — | US | disclosed |
| US-8067594-B2 | Process for the production of benzopyran-2-ol derivatives | PFIZER INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100292502-A1 | Method for preparing high-purity fesoterodine fumarate | CHEMI S.P.A. (IT) | 2010-11-18 | — | — | US | disclosed |
| US-20100292502-A1 | Method for preparing high-purity fesoterodine fumarate | CHEMI S.P.A. (IT) | 2010-11-18 | — | — | US | disclosed |
| EP-2251318-A1 | Method for preparing fesoterodine fumarate | Chemi SPA (IT) | 2010-11-17 | — | — | EP | disclosed |
| EP-2029567-B1 | PROCESS FOR THE PRODUCTION OF BENZOPYRAN-2-OL DERIVATIVES | PFIZER LTD (GB) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010018484-A1 | NEW USES OF DIISOPROPYLAMINE DERIVATIVES | PFIZER LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| US-20090306384-A1 | Process for the Production of Benzopyran-2-ol Derivatives | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031796-A1 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES | ADRA2B, ADRB2, ADRA1B | CHRM2 9/4885CHRM1 60/4885HCAR2 3050/4885 |
| US-20140303396-A1 | Method for Preparing High-Purity Fesoterodine Fumarate | FES, SDHA, FGFR1 | CHRM2 1710/4885CHRM1 3098/4885HCAR2 1999/4885 |
| US-20090306384-A1 | Process for the Production of Benzopyran-2-ol Derivatives | ADRB2, TACR2, TACR1 | CHRM2 32/4885CHRM1 168/4885HCAR2 182/4885 |
| US-20100292502-A1 | Method for preparing high-purity fesoterodine fumarate | FES, SDHA, FGFR1 | CHRM2 1710/4885CHRM1 3098/4885HCAR2 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.